The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Puberty, Precocious

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Puberty, Precocious

 

Psychiatry related information on Puberty, Precocious

 

High impact information on Puberty, Precocious

 

Chemical compound and disease context of Puberty, Precocious

 

Biological context of Puberty, Precocious

 

Anatomical context of Puberty, Precocious

 

Gene context of Puberty, Precocious

 

Analytical, diagnostic and therapeutic context of Puberty, Precocious

References

  1. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. Feuillan, P.P., Foster, C.M., Pescovitz, O.H., Hench, K.D., Shawker, T., Dwyer, A., Malley, J.D., Barnes, K., Loriaux, D.L., Cutler, G.B. N. Engl. J. Med. (1986) [Pubmed]
  2. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. Leet, A.I., Chebli, C., Kushner, H., Chen, C.C., Kelly, M.H., Brillante, B.A., Robey, P.G., Bianco, P., Wientroub, S., Collins, M.T. J. Bone Miner. Res. (2004) [Pubmed]
  3. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty. Comite, F., Pescovitz, O.H., Rieth, K.G., Dwyer, A.J., Hench, K., McNemar, A., Loriaux, D.L., Cutler, G.B. J. Clin. Endocrinol. Metab. (1984) [Pubmed]
  4. Naloxone-induced luteinizing hormone secretion in normal, precocious, and delayed puberty. Petraglia, F., Bernasconi, S., Iughetti, L., Loche, S., Romanini, F., Facchinetti, F., Marcellini, C., Genazzani, A.R. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  5. Testolactone-associated high androgen levels, a pharmacologic effect or a laboratory artifact? Cummings, E.A., Salisbury, S.R., Givner, M.L., Rittmaster, R.S. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  6. Genomic mapping of chromosomal region 2p15-p21 (D2S378-D2S391): integration of Genemap'98 within a framework of yeast and bacterial artificial chromosomes. Kirschner, L.S., Taymans, S.E., Pack, S., Pak, E., Pike, B.L., Chandrasekharappa, S.C., Zhuang, Z., Stratakis, C.A. Genomics (1999) [Pubmed]
  7. Pilodentoungulardysplasia with microcephaly: a new ectodermal dysplasia/malformation syndrome. Tajara, E.H., Pinheiro, M., Freire-Maia, N. Am. J. Med. Genet. (1987) [Pubmed]
  8. Growth hormone responses to sleep, insulin hypoglycaemia and arginine infusion. Ward, P.S., Savage, D.C. Horm. Res. (1985) [Pubmed]
  9. Parenting a daughter with precocious puberty or Turner syndrome. Williams, J.K. Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners. (1995) [Pubmed]
  10. A novel testis-stimulating factor in familial male precocious puberty. Manasco, P.K., Girton, M.E., Diggs, R.L., Doppman, J.L., Feuillan, P.P., Barnes, K.M., Cutler, G.B., Loriaux, D.L., Albertson, B.D. N. Engl. J. Med. (1991) [Pubmed]
  11. Treatment of familial male precocious puberty with spironolactone and testolactone. Laue, L., Kenigsberg, D., Pescovitz, O.H., Hench, K.D., Barnes, K.M., Loriaux, D.L., Cutler, G.B. N. Engl. J. Med. (1989) [Pubmed]
  12. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. Holland, F.J., Fishman, L., Bailey, J.D., Fazekas, A.T. N. Engl. J. Med. (1985) [Pubmed]
  13. Male-limited familial precocious puberty in three generations. Apparent Leydig-cell autonomy and elevated glycoprotein hormone alpha subunit. Reiter, E.O., Brown, R.S., Longcope, C., Beitins, I.Z. N. Engl. J. Med. (1984) [Pubmed]
  14. Familial precocious puberty associated with isolated elevation of luteinizing hormone. Rosenfeld, R.G., Reitz, R.E., King, A.B., Hintz, R.L. N. Engl. J. Med. (1980) [Pubmed]
  15. Puberty in monkeys is triggered by chemical stimulation of the hypothalamus. Plant, T.M., Gay, V.L., Marshall, G.R., Arslan, M. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  16. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. Badaru, A., Wilson, D.M., Bachrach, L.K., Fechner, P., Gandrud, L.M., Durham, E., Wintergerst, K., Chi, C., Klein, K.O., Neely, E.K. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  17. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty. Palmert, M.R., Radovick, S., Boepple, P.A. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  18. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Laue, L., Chan, W.Y., Hsueh, A.J., Kudo, M., Hsu, S.Y., Wu, S.M., Blomberg, L., Cutler, G.B. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  19. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. Heger, S., Partsch, C.J., Sippell, W.G. J. Clin. Endocrinol. Metab. (1999) [Pubmed]
  20. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. Jay, N., Mansfield, M.J., Blizzard, R.M., Crowley, W.F., Schoenfeld, D., Rhubin, L., Boepple, P.A. J. Clin. Endocrinol. Metab. (1992) [Pubmed]
  21. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis. Styne, D.M., Harris, D.A., Egli, C.A., Conte, F.A., Kaplan, S.L., Rivier, J., Vale, W., Grumbach, M.M. J. Clin. Endocrinol. Metab. (1985) [Pubmed]
  22. Rapid GDP release from Gs alpha in patients with gain and loss of endocrine function. Iiri, T., Herzmark, P., Nakamoto, J.M., van Dop, C., Bourne, H.R. Nature (1994) [Pubmed]
  23. Detection of human growth hormone receptors on IM-9 cells and peripheral blood mononuclear cell subsets by flow cytometry: correlation with growth hormone-binding protein levels. Rapaport, R., Sills, I.N., Green, L., Barrett, P., Labus, J., Skuza, K.A., Chartoff, A., Goode, L., Stene, M., Petersen, B.H. J. Clin. Endocrinol. Metab. (1995) [Pubmed]
  24. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues. Jensen, A.M., Brocks, V., Holm, K., Laursen, E.M., Müller, J. J. Pediatr. (1998) [Pubmed]
  25. Effects of acute stanozolol treatment on puberty in female rats. Whitney, A.C., Clark, A.S. Biol. Reprod. (2001) [Pubmed]
  26. Precocious puberty in children with neurofibromatosis type 1. Habiby, R., Silverman, B., Listernick, R., Charrow, J. J. Pediatr. (1995) [Pubmed]
  27. Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls. Xin, X., Luan, X., Xiao, J., Wei, D., Wang, J., Lu, D., Yang, S. Neurosci. Lett. (2005) [Pubmed]
  28. Prolactin response to thyrotropin-releasing hormone in children with gynecomastia, premature thelarche and idiopathic precocious puberty. Abe, K., Matsuura, N., Nohara, Y., Fujita, H., Fujieda, K., Kato, T., Mikami, Y. Tohoku J. Exp. Med. (1984) [Pubmed]
  29. Assessment of seminiferous tubule function (anti-müllerian hormone). Rey, R. Baillière's best practice & research. Clinical endocrinology & metabolism. (2000) [Pubmed]
  30. Genetic aspects of congenital adrenal hyperplasia. Dacou-Voutetakis, C., Maniati-Christidi, M., Dracopoulou-Vabouli, M. Journal of pediatric endocrinology & metabolism : JPEM. (2001) [Pubmed]
  31. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. Tanaka, T., Niimi, H., Matsuo, N., Fujieda, K., Tachibana, K., Ohyama, K., Satoh, M., Kugu, K. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  32. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). Carel, J.C., Lahlou, N., Jaramillo, O., Montauban, V., Teinturier, C., Colle, M., Lucas, C., Chaussain, J.L. J. Clin. Endocrinol. Metab. (2002) [Pubmed]
  33. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. Holland, F.J., Fishman, L., Costigan, D.C., Luna, L., Leeder, S. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  34. Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone. Adams, L.A., Bremner, W.J., Nestor, J.J., Vickery, B.H., Steiner, R.A. J. Clin. Endocrinol. Metab. (1986) [Pubmed]
  35. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty. Kamp, G.A., Manasco, P.K., Barnes, K.M., Jones, J., Rose, S.R., Hill, S.C., Cutler, G.B. J. Clin. Endocrinol. Metab. (1991) [Pubmed]
 
WikiGenes - Universities